Overview

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fasted conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Roxane Laboratories
Treatments:
Carbamazepine
Oxcarbazepine